The Life Sciences team advised Verseau Therapeutics on its partnership agreement with 3SBio Inc. (HKEX:1530) focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. Under the terms of the agreement, 3SBio will receive an exclusive license to develop and commercialize a select number of MCM (Macrophage Checkpoint Modulators) antibodies for all human oncology indications in Greater China, including mainland China, Taiwan, Hong Kong and Macau. Verseau will be responsible for discovery and optimization of MCM antibodies for each program. 3SBio will fund and conduct antibody development, GMP manufacturing, and commercialization in the Territory. Verseau and 3SBio will be eligible to receive certain milestone payments and royalties on product sales both in the territory and globally. 3SBio will also purchase $15 million of Verseau Series B preferred stock. Additional financial terms were not disclosed.
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company’s proprietary all-human translational system identifies novel targets and develop therapies that shift macrophages between immune activators and silencers in disease.
For additional details on the agreement, please read the press release.